{
  "docId": "019de074-1317-767b-825b-77b5f795fc6c",
  "docSlug": "27adacda91e6c92061c4de59bd9e9dc9",
  "documentTitle": "Theravance Biopharma | Investor Conference Presentation Deck | 44 slides",
  "authorId": "theravance-biopharma",
  "authorName": "Theravance Biopharma",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-11-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 44,
  "pageCount": 44,
  "prevPage": 43,
  "nextPage": null,
  "slideType": "timeline",
  "function": "present_framework",
  "density": "balanced",
  "nDataPoints": 0,
  "notes": "The slide uses a tree metaphor for the study name 'CYPRESS'.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de074-1317-767b-825b-77b5f795fc6c/44",
  "deckHref": "/decks/019de074-1317-767b-825b-77b5f795fc6c",
  "deckJsonHref": "/decks/019de074-1317-767b-825b-77b5f795fc6c.json",
  "deckAnchorHref": "/decks/019de074-1317-767b-825b-77b5f795fc6c#slide-44",
  "components": [
    {
      "bbox": {
        "h": 0.5,
        "w": 0.82,
        "x": 0.09,
        "y": 0.2
      },
      "kind": "diagram",
      "text": "Phase 3 registrational study leading to Long-term extension",
      "attrs": null,
      "subkind": "process",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "cd52b3fd-cce5-466f-baa0-fa701d3bc00b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.5,
        "x": 0.09,
        "y": 0.76
      },
      "kind": "list",
      "text": "CYPRESS study initiation planned for first quarter of 2023",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "269639c0-9591-4041-9a84-14c4ac2e1b73",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.02,
        "w": 0.35,
        "x": 0.04,
        "y": 0.925
      },
      "kind": "source-note",
      "text": "MSA, multiple system atrophy; nOH, neurogenic orthostatic hypotension.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "04e68bbc-b378-4edb-9840-7b23ce96ff4b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.45,
        "x": 0.04,
        "y": 0.04
      },
      "kind": "title",
      "text": "New Ampreloxetine Study in Patients With MSA",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e5c5da12-81d2-4927-a122-6d7e8af03ec4",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "timeline",
      "slug": null,
      "matchId": "a0376c15-63d5-4cfd-8d2b-0dcb775babec",
      "evidence": "Sequential progression from Phase 3 study to long-term extension",
      "confidence": 0.9
    }
  ],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}